Purpose

Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.

Conditions

Eligibility

Eligible Ages
Between 12 Years and 110 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Between the ages of 12-110 years old - Has a recently completed COVID test - Symptomatic and seeking treatment - Willingness to participate and have follow-up - Able and willing to take medications and treatment suggestions from the physician

Exclusion Criteria

Lack of symptoms, uncertain of COVID-19 status, outside of age limits for treatment - No recent COVID test results - Asymptomatic, even if COVID positive - Outside of acceptable age range - Meets criteria for hospital admission - Unwilling to participate in trial study or have follow-up

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
COVID-19 patients treated with Ivermectin This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.
  • Drug: Ivermectin
    Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.
    Other names:
    • Vitamin C
    • Vitamin D
    • Quercetin
    • Zinc
    • Budesonide
    • Aspirin
    • Tylenol
    • Ibuprofen
    • IV Infusion
    • Monoclonal Antibodies
    • COVID Vaccine
    • Melatonin
    • Niacin
    • Albuterol
    • Remdesivir
COVID-19 patients declining Ivermectin and wanting traditional treatment This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.

Recruiting Locations

Patrick Robinson MD LLC
San Antonio, Florida 33576
Contact:
Patrick R Robinson, MD
386-237-7150
mustang6374@yahoo.com

More Details

NCT ID
NCT05045937
Status
Unknown status
Sponsor
Patrick Robinson

Study Contact

Patrick R Robinson, MD
3862377150
mustang6374@yahoo.com

Detailed Description

Patients at local physician clinics as well as my own clinic will be enrolled at the time they are evaluated for having COVID-19. Patients enrollment will be voluntary and based upon their request for treatment with Ivermectin. These patients will be questioned on symptoms and the timing of those symptoms in detail. They will then be followed throughout their treatment course to evaluate their recovery experience. Detailed accounts of their symptoms and their resolution will be followed. The study patients will stop being followed when they are either admitted to the hospital or are deemed to be symptom free. Any other medications prescribed to the patients will also be tracked. Medical histories will be taken and documented to make comparisons at the end of the study. Those patients not requesting Ivermectin will also be followed for comparisons at a later date.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.